The International Human Frontier Science Program Organization (HFSPO) is pleased to award the 2026 HFSP Nakasone Award to ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...